1 6 F e b r u a r y 2 0 1 7 | V O L 5 4 2 | N a T u r e | 3 5 7 LeTTer Metabolic pathways that contribute to adiposity and ageing are activated by the mammalian target of rapamycin complex 1 (mTORC1) and p70 ribosomal protein S6 kinase 1 (S6K1) axis 1-3 . However, known mTORC1-S6K1 targets do not account for observed loss-of-function phenotypes, suggesting that there are additional downstream effectors of this pathway 4-6 . Here we identify glutamylprolyl-tRNA synthetase (EPRS) as an mTORC1-S6K1 target that contributes to adiposity and ageing. Phosphorylation of EPRS at Ser999 by mTORC1-S6K1 induces its release from the aminoacyl tRNA multisynthetase complex, which is required for execution of noncanonical functions of EPRS beyond protein synthesis 7,8 . To investigate the physiological function of EPRS phosphorylation, we generated Eprs knock-in mice bearing phospho-deficient Ser999-to-Ala (S999A) and phospho-mimetic (S999D) mutations. Homozygous S999A mice exhibited low body weight, reduced adipose tissue mass, and increased lifespan, similar to S6K1-deficient mice 9-11 and mice with adipocyte-specific deficiency of raptor, an mTORC1 constituent 12 . Substitution of the Eprs S999D allele in S6K1deficient mice normalized body mass and adiposity, indicating that EPRS phosphorylation mediates S6K1-dependent metabolic responses. In adipocytes, insulin stimulated S6K1-dependent EPRS phosphorylation and release from the multisynthetase complex. Interaction screening revealed that phospho-EPRS binds SLC27A1 (that is, fatty acid transport protein 1, FATP1) 13-15 , inducing its translocation to the plasma membrane and long-chain fatty acid uptake. Thus, EPRS and FATP1 are terminal mTORC1-S6K1 axis effectors that are critical for metabolic phenotypes.
and U937 cells specifically inhibited EPRS Ser999 phosphorylation ( Fig. 1c, Extended Data Fig. 1c ). Endogenous phosphorylation using anti-phospho-Ser999 EPRS antibody 7 and in vitro phosphorylation of Ser999 linker by lysates from IFNγ -treated bone-marrowderived macrophages (BMDM) from S6K2 −/− (also known as Rps6kb2 −/− ), but not S6K1 −/− (Rps6kb1 −/− ) and S6K1 −/− S6K2 −/− doubleknockout mice, confirmed the requirement for S6K1 ( Fig. 1d ). Co-immunoprecipitation assay showed that IFNγ induced S6K1 binding to EPRS, suggesting that S6K1 is the proximal kinase ( Fig. 1e ). Finally, recombinant S6K1 phosphorylated Ser999 in S886A linker ( Fig. 1f , Extended Data Fig. 1d ). Rapamycin, an mTORC1 inhibitor 18 , inhibited S6K1 phosphorylation at the classical Thr389 activation site, and suppressed EPRS Ser999 phosphorylation (Fig. 1g ), as did short interfering RNA (siRNA) targeting the mTORC1 constituent, raptor, but not the mTORC2 constituent, rictor 2, 18 (Extended Data Fig. 1e ). To verify the mTORC1 requirement, S6K1 was suppressed with siRNA targeting the 3′ UTR, and Myc-tagged S6K1 bearing a phospho-defective mutation at Thr389 was introduced (Extended Data Fig. 1f, g) . The phospho-defective S6K1(T389A) mutant, but not the phospho-mimetic T389E mutant, was unable to bind and phosphorylate EPRS (Extended Data Fig. 1g, h) . These results establish the requirement for mTORC1-activated S6K1 to phosphorylate EPRS at Ser999 (Fig. 1a) .
To investigate the physiological role of EPRS phosphorylation, homozygous phospho-defective (Ser999-to-Ala; denoted as Eprs A/A ) and phospho-mimetic (Ser999-to-Asp; Eprs D/D ) knock-in mice in C57BL/6 background were generated by homologous recombination and verified (Extended Data Fig. 2a, b ). Progeny of heterozygous crosses of both models exhibited near-Mendelian genotype distribution, indicating no apparent developmental defects (Extended Data Fig. 2c ). Importantly, adult male and female Eprs A/A , but not Eprs D/D , mice exhibited about 15-20% lower weight than wild-type Eprs S/S mice ( Fig. 2a , Extended Data Fig. 2d ). The weight difference was not observed in embryonic or early developmental stages, but began at 8-10 weeks ( Fig. 2a , Extended Data Fig. 2e , f). Marked lifespan increase was observed for both genders of Eprs A/A mice; the combined median increase was about 118 days or 15% ( Fig. 2b and Extended Data Fig. 3a ). Cox regression analysis revealed genotype, not gender, date of birth, or parental ID, as the most dominant predictor of longevity with a hazard ratio substantially greater than one (Extended Data Fig. 3b ). No change in lifespan was observed in Eprs D/D mice (Extended Data Fig. 3c-e ).
The body length of Eprs A/A mice was same as wild-type, however, the opened abdominal cavity revealed reduced adipose tissue in Eprs A/A mice (Extended Data Fig. 4a, b ). The mass of major white adipose tissue (WAT) depots and interscapular brown adipose tissue (IBAT) in Eprs A/A was about half of that in Eprs S/S mice, but other major organs were unchanged (Fig. 2c ); no mass differences were observed in Eprs D/D mice (Extended Data Fig. 4c ). Reduced adipocyte size and unaltered letter reSeArCH number was observed in Eprs A/A mice (Fig. 2d , Extended Data Fig. 4d, e ). Lipolysis and fatty acid β -oxidation were greater in Eprs A/A (Extended Data Fig. 4f, g) . Serum glucose, triglycerides, and free fatty acid levels were unaltered in Eprs A/A mice, but insulin level was reduced (Extended Data Fig. 4h ). High-fat diet (~ 60% total calories from fat) feeding induced EPRS phosphorylation in wild-type adipose tissue, and letter reSeArCH body weight gain was substantially reduced in Eprs A/A mice (Extended Data Fig. 4i , j). These characteristics of Eprs A/A mice approximately phenocopy S6K1-null and adipocyte-specific, raptor-deficient mice, suggesting EPRS as mTORC1-S6K1 effector contributing to obesityrelated phenotypes 9,10,12 . To test this relationship, we bred phosphomimetic Eprs D/D alleles into S6K1 −/− mice generated on a C57Bl/6 background by targeted disruption 19 . Like the previously characterized S6K1 −/− line 9,20 , the mice were small; however, obesity-related phenotypes were not investigated. Gene deletion was verified by genotyping and protein absence in adipocytes (Extended Data Fig. 5a, b ). As before, this S6K1 −/− line exhibited reduced body weight in embryos and early developmental stages 9 (Extended Data Fig. 5c ). Lifespan extension of about 170 d or 22% was observed in combined genders of S6K1 −/− mice (Extended Data Fig. 5d-f ). Introduction of the S999D gain-of-function allele into S6K1 −/− mice resulted in about 60% restoration of body and WAT mass towards wild-type, that is, Eprs S/S S6K1 +/+ , mice ( Fig. 2e , f) indicating S6K1-mediated EPRS phosphorylation is a critical determinant of adiposity 9,10,12 . Incomplete restoration might indicate contributions of other established or as-yet unidentified mTORC1-S6K1 targets 4, 6, 21 .
Carbohydrate metabolism was investigated in EPRS mutant mice by glucose and insulin tolerance tests (GTT and ITT, respectively). Young adult (112 days old) Eprs A/A mice exhibited slower glucose clearance following bolus injection of glucose, but faster clearance following insulin injection (Extended Data Fig. 6a, b ). This paradoxical result is similar to observations in S6K1 −/− mice 10, 22 . Older (about 600 days old) Eprs A/A mice metabolized glucose more quickly, as analysed by both GTT and ITT (Extended Data Fig. 6c, d ). Glucose metabolism was identical in Eprs D/D and wild-type mice, both young and old (Extended Data Fig. 6a-d ). Food intake, faecal lipid excretion, and ketone body formation were essentially identical in Eprs A/A , Eprs D/D , and wildtype mice (Extended Data Fig. 6e -i). O 2 consumption (VO 2 ) and CO 2 release (VCO 2 ) were substantially higher in Eprs A/A mice compared to wild-type, both in the dark (as expected for nocturnal animals) and light phases, as observed in S6K1 −/− mice 9 (Extended Data Fig. 7a , b). The respiratory exchange ratio trended towards lower indicative of greater fat utilization (Extended Data Fig. 7c ). Energy expenditure determined as heat output was significantly higher in Eprs A/A mice (Extended Data Fig. 7d ). Energy balance in Eprs D/D mice was not significantly different from the wild-type (Extended Data Fig. 7e -h). Female Eprs mutant mice showed O 2 consumption similar to males (Extended Data Fig. 7i ).
In view of reduced Eprs A/A adipocyte size, and critical role of EPRS in translation, we established that total protein synthesis in adipocytes was not disrupted (Extended Data Fig. 8a ). Importantly, insulin, a principal agonist of mTORC1-S6K1 activation and adipocyte anabolic activity 23 , induced robust Ser999 phosphorylation in adipocytes from Eprs S/S mice; phosphorylation was abrogated in Eprs A/A mice despite S6K1 activation as detected by phosphorylation of S6K1 and its RPS6 target ( Fig. 3a ). Like myeloid cells, EPRS phosphorylation in adipocytes required mTORC1 and S6K1 (Extended Data Fig. 8b ). EPRS phosphorylation in mouse adipocytes or differentiated 3T3-L1 cells was not stimulated by IFNγ , the activator of EPRS and GAIT pathway in myeloid cells (Extended Data Fig. 8c ). Likewise, insulin did not induce GAIT complex assembly or repress in vitro translation of GAIT element-bearing transcript in differentiated 3T3-L1 cells (Extended Data Fig. 8d, e ). To determine the potential role of inflammation in the lean phenotype of Eprs A/A mice, we determined white blood cell levels and found no statistically significant differences between Eprs A/A and wild-type mice in any leukocyte type (Extended Data Fig. 8f ). Analysis letter reSeArCH of an anti-cytokine array showed differential expression of CC27 only, but the difference was not validated by immunoblot (Extended Data Fig. 8g, h) .
Insulin-stimulated long-chain fatty acid (LCFA) uptake was significantly reduced in Eprs A/A but not Eprs D/D mouse adipocytes; glucose uptake was essentially identical (Fig. 3b ). Insulin-stimulated LCFA uptake did not require EPRS phosphorylation in liver, heart, muscle, or BMDM (Extended Data Fig. 9a ). Notably, a requirement for S6K1 in insulin-stimulated EPRS phosphorylation and LCFA uptake in adipocytes was observed (Extended Data Fig. 9b ). Fatty acid binding proteins and transporters, together with lipolytic enzymes and a glucose transporter, were screened to identify potential downstream targets of phospho-EPRS. Insulin-dependent interaction of EPRS was observed exclusively with the fatty acid transporter, FATP1, a principal mediator of insulin-stimulated LCFA uptake in adipocytes 14, 24 (Fig. 3c ). Insulin reduced EPRS association with two multisynthetase complex constituents, AIMP3 and lysyl tRNA synthetase, establishing stimulus-dependent release from the parental complex ( Fig. 3c ). Interaction between phospho-EPRS and FATP1 was confirmed by co-immunoprecipitation, and binding was inhibited by S6K1 knockdown or rapamycin ( Fig. 3d ). Likewise, the inhibitors reduced insulin-stimulated uptake of bodipy-C 12 , a fluorescent LCFA analogue, and [ 14 C]oleic acid ( Fig. 3e ). Knockdown of EPRS or FATP1 by about 60% reduced LCFA uptake by about half, and knockdown of both further reduced uptake to near background, without inhibiting protein synthesis ( Fig. 3f , Extended Data Fig. 9c ). EPRS interaction with FATP1 was repressed in Eprs A/A mouse adipocytes indicating a strict requirement for Ser999 phosphorylation ( Fig. 3g ). Similar binding characteristics and LCFA uptake were observed in human adipocytes (Extended Data Fig. 9d ). However, insulin-stimulated EPRS-FATP1 interaction was not observed in non-adipose tissues, suggesting a requirement for adipocyte-specific factors (Extended Data Fig. 9e ). Also, interaction of EPRS with FATP1 was not seen in adipose tissue from S6K1 −/− mice (Extended Data Fig. 9f , g). These results implicate EPRS and FATP1 as critical downstream effectors of mTORC1-S6K1 specifically contributing to adiposity. Low LCFA uptake by Eprs A/A adipocytes could increase serum or hepatic lipid levels with pathological consequences. However, serum lipids in fed and fasted mice, and liver triglycerides and neutral lipids, revealed no statistically significant differences (Extended Data Figs 4h, 10a, b), Individual EPRS domains, catalytic ERS and PRS, and the connecting linker, were expressed in adipocytes in which endogenous mouse EPRS was repressed by 3′ -UTR-specific siRNA (Fig. 4a ). Insulin induced linker phosphorylation and interaction with FATP1, which in turn enhanced LCFA uptake ( Fig. 4a ). FATP1 failed to bind the S999A mutant linker, but bound the S999D mutant even without insulin stimulation; LCFA uptake likewise required Ser999 phosphorylation ( Fig. 4b ). As shown by others, insulin induced FATP1 translocation from cytoplasm to membranes 14 (Fig. 4c ). Insulin-stimulated translocation required EPRS phosphorylation as EPRS and FATP1 localization in membranes was reduced in Eprs A/A adipocytes; in contrast, both translocated to membranes in Eprs D/D adipocytes even in the absence of insulin (Extended Data Fig. 10c ). EPRS knockdown markedly reduced FATP1 membrane localization, but not vice versa, indicating EPRS is critical for FATP1 translocation (Fig. 4d ). Membrane fractionation showed insulin induced FATP1 and EPRS translocation specifically to plasma membranes (Extended Data Fig. 10d ).
The metabolic phenotype of Eprs A/A mice captures several salient features of S6K1 −/− mice. They exhibit unaltered food intake, small adipocytes, reduced adiposity and body weight, improved glucose homeostasis in adults, and increased energy expenditure. Adipocytes from both mouse types have reduced insulin-stimulated EPRS binding to FATP1 and LCFA uptake, and enhanced basal lipolysis. We observed extended lifespan in Eprs A/A and S6K1 −/− mice of both genders; a previous report showed significant longevity increase in female S6K1 −/− mice, with similar trend for males 10 . However, S6K1 −/− mice have reduced body weight at an earlier stage in development, and reduced muscle mass 20, 25 . These differences might be explained by the breadth of S6K1 targets with multiple functions in diverse organ systems 6, 11, 21, 26 . The phenotypic relationship between Eprs A/A and Fatp1 −/− mice is less clear. Both mice exhibit markedly reduced adipocyte size and epididymal fat mass 13 . However, reduced body , and LCFA uptake. Endogenous mouse EPRS in 3T3-L1 adipocytes was knocked down by 3′ -UTR-specific siRNA and cells transfected with Flag-tagged EPRS domains (ERS, PRS, and linker), and insulin-stimulated phosphorylation determined by 32 P-labelling (left). Binding of EPRS domains to FATP1 was detected by co-immunoprecipitation, and LCFA uptake measured (mean ± s.e.m., n = 4 experiments in duplicate) (right). b, Expression of phospho-mimetic S999D linker facilitates interaction with FATP1 and fatty acid uptake even without insulin (mean ± s.e.m., n = 3 experiments in duplicate). c, Insulin induces translocation of Ser999-phosphorylated EPRS and FATP1 to membranes. Anti-GAPDH and anti-Na + /K + -ATPase antibodies verified cytosolic and membrane isolation. d, Effect of knockdown of EPRS (left) and FATP1 (targeting the coding sequence (CDS), right) on translocation to membrane. e, Schematic of mTORC1-S6K1 activation of EPRS-and FATP1mediated LCFA uptake in adipocytes. MSC, multisynthase complex; TG, triglycerides..
letter reSeArCH
weight was not observed in Fatp1 −/− mice. Possibly, the difference is explained by genetic background, compensatory upregulation of an alternative LCFA uptake mechanism in a knockout 27 , or by calculation of body weight as fraction of initial weight that can reduce apparent differences at later times 13 .
Adipocyte triglyceride accumulation is largely determined by relative fluxes through catalytic reactions driving LCFA uptake, its esterification to glycerol backbones, glyceride lipolysis, and β -oxidation. Phospho-EPRS enhances the first step by activating FATP1, and EPRS knockdown inhibits adipocyte LCFA uptake by ~ 50%. Interestingly, others report that depletion of FATP1 and CD36 reduces adipocyte LCFA uptake by ~ 25% and 60-70%, respectively, suggesting EPRS stimulates FATP1-independent uptake mechanisms 28, 29 . Although stable interaction of EPRS was detected only with FATP1, we have not eliminated the possibility that EPRS activates transport by indirect mechanisms or by transient interactions not captured by immunoprecipitation. We also provide evidence that EPRS phosphorylation contributes to lipid accumulation by inhibiting catabolic reactions, that is, lipolysis and fatty acid oxidation.
The mTORC1-S6K1 axis is central to metabolic pathways 1-3 , but established axis targets do not account for all observed loss-of-function metabolic phenotypes [4] [5] [6] . Our studies reveal an unexpected adipogenic pathway resulting from mTORC1-S6K1 activation of EPRS ( Fig. 4e ). EPRS belongs to the S6K1 substrate class, site-specifically phosphorylated despite the lack of the established kinase recognition sequence, R/KXRXXS/T 6 . Phospho-EPRS contributes to adiposity through membrane translocation and activation of FATP1, which stimulates LCFA uptake by an unresolved mechanism that might feature facilitated transport, or intracellular metabolic trapping by long-chain fatty acyl coenzyme A synthetase activity of FATP1 or by ligation of FATP1 to a distinct acyl coenzyme A synthetase 30 . The binding of FATP1 to the non-catalytic linker domain in EPRS is consistent with the known binding promiscuity of linker WHEP domains, and the recent recognition that late-evolving, appended domains are largely responsible for noncanonical functions of multiple tRNA synthetases 16 . The noncatalytic domain represents a potential therapeutic target for obesity and ageingrelated disorders.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. letter reSeArCH MethOdS Data reporting. No statistical methods were used to predetermine sample size. Reagents. Affinity-purified antibodies against total and Ser886 and Ser999 phosphosites of EPRS were generated as described 7, 31 . Antibody against phospho-Ser was from Meridian Life Science. Antibodies specific for the C terminus of S6K1 and N terminus of S6K2 were purchased from Abcam and LifeSpan, respectively. Antibodies against PKA, DMPK, PKN, GAPDH, caveolin1, CD36/ FAT, GLUT4, His-tag, β -actin and FATP1, FATP3, and FATP4 were from Santa Cruz. Antibody specific for FABP4 and FABP5 were from R&D and for FABPpm/ GOT2 was from GeneTex. All other antibodies and rapamycin were from Cell Signaling. SignalSilence siRNAs targeting RSK1, AKT and S6K1 were from Cell Signaling, and those targeting raptor and rictor were from Santa Cruz. The 3′ -UTR-specific duplex siRNAs, 5′ -UGAUACGAAGAUCUUCUCAG-3′ and 5′ -GCCUAAAUUAACAGUGGAA-3′ , targeting mouse EPRS were from Origene. Smart pool siRNA targeting the coding sequence of mouse FATP1 (SLC27a1) was from Dharmacon and 3′ -UTR-specific trilencer siRNA targeting human S6K1 was from Origene. Plasmids and proteins. Recombinant wild-type and Ser-to-Ala (S886A and S999A) mutant His-tagged linker proteins spanning Pro683 to Asn1023 of human EPRS were expressed and purified as described 7, 8 . Recombinant active S6K1 (ref. 32 ) and RSK1-3 were from Cell Signaling; Akt1 and Akt2 were from EMD Millipore. Mouse EPRS domains ERS (Met 1 to Gln682), linker (Pro683 to Asn1023), and PRS (Leu1024 to Tyr1512) were cloned into pcDNA3 vector with an N terminus Flag tag using full-length mouse EPRS cDNA (Origene) as template. Flag-tagged mouse wild-type linker and linker with Ser999-to-Ala (S999A) and Ser999-to-Asp (S999D) mutations were generated as described 33 . Full-length human S6K1 cDNA in pCMV6-entry vector was purchased from Origene and recloned, deleting the 23-amino acid N terminus nuclear localization signal, and adding an in-frame upstream 6-His tag and a downstream Myc tag in pcDNA3. Specific Thr389-to-Ala (T389A) and Thr389-to-Glu (T389E) mutations were introduced using primers with the desired mutation and GENEART Site-Directed Mutagenesis System (Invitrogen). Cell culture. Human U937 monocytic cells (CRL 1593.2; ATCC authenticated by STR DNA profiling) were cultured in RPMI 1640 medium and 10% fetal bovine serum (FBS) with penicillin and streptomycin at 37 °C in 5% CO 2 . Bone-marrowderived macrophages (BMDM) were flushed from femur and tibia marrows of S6K1 −/− S6K2 −/− , and double-knockout S6K1 −/− S6K2 −/− mice (from G. Thomas and S. Kozma), and then cultured for one week in RPMI 1640 medium containing 10% FBS and 20% L929 cell-conditioned medium at 37 °C in 5% CO 2 . 1 × 10 7 cells were treated with 500 U ml −1 IFNγ (R&D) for up to 24 h, as described previously 34, 35 . 3T3-L1 fibroblasts (CL-173; ATCC-certified) were cultured in high glucose containing Dulbecco's modified Eagle's medium (DMEM), 10% FBS and antibiotics/antimycotic at 37 °C in 10% CO 2 to near 75% confluence. Confluent fibroblasts were induced to differentiate in medium containing DMEM and 10% FBS supplemented with 1× solutions of insulin:dexamethasone:3-isobutyl-1-methylxanthine (Cayman). After 72 h, the medium was replaced with 10% FBS and DMEM containing only insulin and maintained for a week with 3 changes in the same medium. Adipocytes were maintained in DMEM medium with 10% calf serum and antibiotics/antimycotic for at least 3 d before utilization. Differentiated adipocytes were serum-deprived for 4 h followed by treatment with 100 nM insulin (Sigma-Aldrich) for 4 h, or as indicated. Cell lysates were prepared using Phosphosafe Extraction buffer (Novagen) supplemented with protease inhibitors. As certified U937 monocytes and 3T3-L1 fibroblasts were directly procured from ATCC, they were not subjected to any further testing for contamination.
Primary adipocytes from white adipose tissue (WAT) were prepared as described 14, 36 . Briefly, after mouse sacrifice, fat pads were removed and minced in Krebs-Ringer-bicarbonate-HEPES (KRBH) buffer (pH 7.4) containing 10 mM sodium bicarbonate, 30 mM HEPES, 200 nM adenosine, and 1% fatty acid-free bovine serum albumin (BSA, Sigma). WATs were digested with collagenase (2 mg g −1 ) in KRBH buffer at 37 °C for 1 h. Digested WATs were suspended in DMEM supplemented with 10% FBS, and filtered through 100-μ m mesh cell strainer (BD Falcon) to remove undigested material. The cell suspension was incubated for 10 min at room temperature, and adipocytes collected from the floating layer after centrifugation. Adipocytes were incubated for 1 h at room temperature with gentle shaking and washed three times with DMEM.
Differentiated human adipocytes in adipocyte maintenance medium were obtained from Cell Applications. Adipocytes were maintained in DMEM medium with 10% calf serum and antibiotics/antimycotic for 2 d before utilization, and 5 × 10 6 cells were serum-deprived for 4 h followed by treatment with 100 nM insulin for 4 h.
Hepatocytes were isolated by collagenase perfusion of mouse livers and cells seeded for 4 h on collagen-coated 6-well plates (1 × 10 6 cells per well) in Williams' medium E with 10% FBS, 25 mM HEPES, 100 nM insulin, and 100 nM triiodothyronine [37] [38] [39] . Cells were cultured for 48 h in serum-free Williams medium E with two medium changes. Before experiments, hepatocytes were pre-incubated overnight in serum-, insulin-, and triiodothyronine-free DMEM, and then with 100 nM insulin.
Adult mouse cardiac cells were isolated by sequential plating using non-perfusion adult cardiomyocyte isolation kit (Cellutron) 40 . After isolation, 1 × 10 6 cardiac cells were incubated for 24 h in serum containing AS medium, and then with serum-free AW medium for another 24 h. Before experiments, cells were incubated for 4 h in serum-free DMEM, and then with 100 nM insulin.
All studies using cultured cells were repeated at least three times. The number of replicates was estimated from comparable published studies that gave statistically significant results. Transfection. U937 cells (1 × 10 7 ), PBMs and differentiated 3T3-L1 adipocytes (5 × 10 6 cells for both) were transfected with endotoxin-free plasmid DNAs or siRNAs (target-specific and scrambled control) using nucleofector (100 μ l solution V for U937 cells and PBMs and 100 μ l solution L for 3T3-L1 adipocytes) from Amaxa nucleofection kit (Lonza) following the manufacturer's protocol. Transfected cells were immediately transferred to pre-warmed Opti-MEM media for 6 h and then to RPMI 1640 (for U937 cells and PBMs) and DMEM (for 3T3-L1 adipocytes) containing 10% FBS supplemented with penicillin, streptomycin, and geneticin (G418; 20 μ g ml −1 ) for 18 to 24 h before treatment with insulin and inhibitors. In vitro kinase and phosphorylation assays. Cell lysates or purified active kinases were pre-incubated with recombinant EPRS linker (wild-type and mutant) for 5 min in kinase assay buffer (50 mM Tris-HCl (pH 7.6), 1 mM dithiotheitol, 10 mM MgCl 2 , 1 mM CaCl 2 , and phosphatase inhibitor cocktail) 7, 8, 33 . Phosphorylation was initiated by addition of 5 μ Ci [γ -32 P]ATP (Perkin-Elmer) for 15 min, and terminated using SDS gel-loading buffer and heat denaturation. Phosphorylated proteins were detected after resolution on Tris-glycine SDS-PAGE, fixation in 40% methanol and 10% acetic acid, and autoradiography. Immunoblot with anti-His tag antibody to detect EPRS linker served as control. To assay kinase activity using peptide substrates, 50 μ M of synthetic peptides were phosphorylated with 1 μ Ci [γ -32 P]ATP in kinase assay buffer. Equal volumes were spotted onto P81-phosphocellulose squares, washed in 0.5% H 3 PO 4 , and 32 P incorporation determined by scintillation counting. Immunocomplex kinase assay. U937 cell lysates were pre-cleared using protein A-sepharose, and target AGC kinase members and a non-member, MK2 were immunoprecipitated by incubation with specific antibodies for 4 h. The immunocomplex was captured by incubating with protein A-sepharose beads for 4 h, and washed three times with kinase assay buffer supplemented with 0.1% Triton X-100. The immunocomplex was resuspended in kinase assay buffer and used to phosphorylate EPRS linker as above, and 32 P incorporation into peptide substrates was determined by scintillation counting 41 . Target peptides for S6K1, RSK1, MSK1, SGK494, NDR1, MRCKα , CRIK, RSKL1, ROCK1 and 2 (RRRLSSLRA), GRK2 (CKKLGEDQAEEISDDLLEDSLSDEDE), LATS1 (CKKRNRRLSVA), MAST1 (KKSRGDYMTMQIG), PRKX (RRRLSFAEPG), DMPK (KKSRGDYMTMQIG), and PDK1 (KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC) were from SignalChem; for MK2 (KKLNRTLSVA) from Enzo Life Sciences; for PKA (RRKASGP), SGK1/AKT (RPRAATF), PKC/PKN (HPLSRTLSVAAKK), PKG, (RKISASEFDRPLR), and Cdk5 (PKTPKKAKKL) were from Santa Cruz. Mouse husbandry. All mice were housed in microisolator cages (maximum 5 per cage of same-sex littermates) and maintained in climate/temperature-and photoperiod-controlled barrier rooms (22 ± 0.5 °C, 12-12 h dark-light cycle) with unrestricted access to water and standard rodent diet (Harlan Teklad 2918) deriving 24, 18 and 58 kcal% from protein, fat and carbohydrate, respectively. Mice were fed standard rodent diet unless otherwise indicated. The number of animals used in each experiment was estimated from examination of comparable published studies that gave statistically significant results. All mouse studies were performed in compliance with procedures approved by the Cleveland Clinic Lerner Research Institute Institutional Animal Care and Use Committee.
Generation of mice with Eprs S999A and Eprs S999D knock-in mutations.
Genetically-modified EPRS phospho-deficient S999A and phospho-mimetic S999D knock-in mice were generated (Xenogen Biosciences, Taconic). The RP23-86H18 BAC clone from mouse chromosome 1 containing full-length mouse Eprs gene was used to generate 5′ and 3′ homology arms, the knock-in region for the gene targeting vector, and Southern blot probes for screening targeted events. The homology arms and the knock-in region were generated by high-fidelity PCR, and cloned into the pCR4.0 vector. The S999A and S999D mutations (TCA to GCA or GAT, respectively) in exon 20 were introduced by PCR-based sitedirected mutagenesis. The final vector also contained Frt sequences flanking the Neo expression cassette for positive embryonic stem cell selection, and a DTA letter reSeArCH expression cassette for negative selection. The targeting vector was electroporated into C57BL/6 embryonic stem cells and screened with G418. Positive expanded clones with confirmed mutation were selected. Neo was deleted by Flp electroporation, and blastocysts injected. Male chimaeras were bred with C57BL/6 wild-type females, and resulting F1 heterozygotes interbred to generate homozygotes in C57BL/6 background. Genotyping was done using forward primer 5′ -CAGCATAAGAACAGTTGCCAAATAAAGG-3′ and reverse primer 5′ -TTCTTGAACACACACATGCACAGACTC-3′ . For all experiments the wild-type (Eprs S/S ), Eprs A/A and Eprs D/D were generated exclusively by breeding heterozygotes (Eprs S/A and Eprs S/D ), and most experiments shown use male mice unless otherwise indicated. Mice were not randomized and studies were performed unblinded with respect to mouse genotype. Generation of mice with knock-in of Eprs D/D in S6K1-null background. S6K1 −/− mice in C57BL/6 background were generated at the National Jewish Medical and Research Centre (Denver, Colorado) by blastocyst injection of embryonic stem cells with targeted disruption of the S6K1 gene as described previously 19, 42 . Briefly, neomycin (Neo) selection cassette was inserted to disrupt the exon corresponding to amino acids 207-237 in the catalytic domain of S6K1, thereby frame-shifting the downstream coding region. S6K1 −/− mice exhibited phenotypes consistent with the previously reported mice that were generated by similar approach that is, replacing the catalytic domains of S6K1 with a Neo selection cassette 9, 20 . Eprs D/D S6K1 −/− and Eprs S/S S6K1 −/− were generated by Eprs S/D S6K1 −/− × Eprs S/D S6K1 −/− crosses. Mice wild-type for both Eprs and S6K1 genes (Eprs S/S S6K1 +/+ ) were generated from crosses of S6K1 +/− heterozygotes.
Recruitment and determination of Eprs A/A mouse longevity. Male and female mice of Eprs S/S and Eprs
A/A genotypes were recruited (n = 212 total mice) exclusively from crosses of heterozygotes (Eprs S/A ). All mice were housed in microisolator cages (maximum 5 per cage of same-sex littermates) with routine cage maintenance as above. Weaned mice (> 21 days), born between June 2010 and December 2012 from 40 heterozygous parents, were monitored daily and weighed biweekly for the entire duration of their life. Mice that spontaneously developed conditions common in the C57BL/6 strain, such as malocclusion and hydrocephalus, were sacrificed and excluded from the study 43 . Assessments of deterioration in general health and quality of individual life were made in consultation with veterinary services of the Biological Resources Unit (BRU) of the Cleveland Clinic Lerner Research Institute. Severely sick and moribund mice that were judged to not survive another 48 h were euthanized with this date considered date of death, and included in the longevity analysis. Mice euthanized owing to imminent death include 11.5% (6 out of 52) male and 11.1% (6 out of 54) female of Eprs S/S genotype, and 7.7% (4 out of 52) male and 9.3% (5 out of 54) female of Eprs A/A genotype. Longevity was analysed by Kaplan-Meier survival curves from 212 mice (52 male and 54 female of each genotype, Eprs S/S and Eprs A/A ) using known birth and death dates. Statistical differences were evaluated by log-rank Mantel-Cox and Gehan-Breslow-Wilcoxon tests using GraphPad Prism 5. Recruitment and determination of Eprs D/D mouse longevity. Male and female mice of Eprs S/S and Eprs D/D genotypes were recruited (n = 89 total mice) exclusively from crosses of heterozygotes (Eprs S/D ). All weaned mice (> 21 days born between February, 2011 and September, 2014 from 23 Eprs S/D parents) were housed in microisolator cages (maximum 5 per cage of same-sex littermates) with routine cage maintenance and health monitoring as above. Mice killed owing to imminent death (as described above) include 8.7% (2 out of 23) male and 9.5% (2 out of 21) female of Eprs S/S genotype, and 8.3% (2 out of 24) male and 4.8% (1 out of 21) female of Eprs A/A genotype. Longevity was analysed by Kaplan-Meier survival curves from 89 mice (23, 21 male and 24, 21 male of genotype, Eprs S/S and Eprs A/A , respectively) using known birth and death dates and statistical analysis, as above. Recruitment and determination of S6K1 −/− mouse longevity. Male and female mice of S6K1 +/+ and S6K1 −/− genotypes were recruited (n = 112 total mice) exclusively from crosses of heterozygotes (S6K1 +/− ). All weaned mice (> 21 days born between February 2011 and December 2013 from 23 S6K1 +/− parents) were housed in microisolator cages (maximum 5 per cage of same-sex littermates) with routine cage maintenance and health monitoring as above. Mice killed owing to imminent death (as described above) include 13.8% (4 out of 29) male and 10.3% (3 out of 29) female of S6K1 +/+ genotype, and 14.3% (4 out of 28) male and 14.3% (3 out of 21) female of S6K1 −/− genotype. Longevity estimation was analysed by Kaplan-Meier survival curves from 112 mice (29, 29 male and 28, 26 female of genotype, S6K1 +/+ and S6K1 −/− , respectively) using known birth and death dates and statistical analysis as above. Longevity analysis by Cox proportional hazard (CPH) regression. Univariate and multivariate CPH regression models were performed to analyse the effects of 4 variables; genotype, date of birth (DOB), gender, and parental identity (PID), on longevity of mice recruited for the study. The independent variables were fitted as categorical variables in the model. Genotype and gender were coded as binary variables. DOB and PID were coded as multiple categories. For CPH regression analysis of Eprs S/S and Eprs A/A mice (n = 212), the data were coded as follows: genotype, Eprs S/S (1) and Eprs A/A (0); gender, male (0) and female (1) . On the basis of unique occurrences, DOB and PID were categorized into 79 (0-78, 0 being the DOB for oldest mice in the study) and 40 (1-40) categories, respectively. Oldest DOB category represents the reference for DOB. PID-1 was considered reference for PID variable. Models were fit using Cox proportional hazards regression in R package 'survival' using coxph function. Univariate model was built fitting each of the four variables individually and multivariate model was built fitting all four variables simultaneously. For CPH regression analysis of Eprs S/S and Eprs D/D mice (n = 89), the data were coded as follows: genotype, Eprs S/S (1) and Eprs D/D (0); gender, male (0) and female (1) . On the basis of unique occurrences, DOB and PID were categorized into 38 (0-37, 0 being the DOB for oldest mice in the study) and 23 (1-23) categories, respectively. For CPH regression analysis of S6K1 +/+ and S6K1 −/− mice (n = 112), the data were coded as follows: genotype, S6K1 +/+ (1) and S6K1 −/− (0); gender, male (0) and female (1) . On the basis of unique occurrences, DOB and PID were categorized into 36 (0-35, 0 being the DOB for oldest mice in the study) and 23 (1-23) categories, respectively. Scanning electron microscopy. Scanning electron microscopy was performed by the Cleveland Clinic Imaging Core. WAT from 20-week-old male mice was fixed using 2.5% glutaraldehyde and 4% paraformaldehyde in phosphate-buffered saline (PBS) overnight at 4 °C. Tissues were washed three times in PBS followed by post-fixation with 1% osmium tetroxide in PBS for 1 h at 4 °C. Finally, the tissues were dehydrated through graded alcohol (50, 70, 90, and 100%), twice in ethanol:hexamethyldisilizane (HMDS; 1:1), and three times in 100% HMDS for 10 min each, and dried at room temperature. Samples were mounted on aluminium stubs and coated with palladium-gold using a sputter-coater, and viewed at X500 magnification with a Jeol JSM 5310 Electron Microscope (EOL). Histochemistry. Adipose tissues from 20-week-old male mice were fixed in formalin, dehydrated in ethanol, embedded in paraffin, and cut at 5-μ m thickness. Sections were deparaffinized, rehydrated, and stained with haematoxylin and eosin by the Cleveland Clinic Histology Core. Stained tissues were visualized with Leica DM2500 microscope, captured with Micropublisher 5.0 RTV digital camera (QImaging) using a 5X objective lens for magnification, and QCapture Pro 6.0 (QImaging) software for image acquisition. Determination of adipose tissue cell number. Adipocytes from 100 mg EWAT of 20-week male mice were isolated as described above and suspended in DMEM. Cells were counted in a haemocytometer. Lipolysis in primary adipocytes. Basal lipolysis in primary adipocytes from Eprs S/S , Eprs A/A , and Eprs D/D EWAT was measured by glycerol release using adipolysis assay kit (Cayman). Fatty acid oxidation. Fatty acid oxidation in EWAT of 20-week-old male mice was performed as described 13, 44 . Explants were placed in an Erlenmeyer flask (Kimble-chase Kontes) containing the reaction mixture (DMEM with 0.1 μ Ci of [ 14 C]oleic acid, 100 mM l-carnitine, and 0.2% fat-free BSA), and conditioned for 5 min in a 37 °C CO 2 incubator. The flask was sealed with a rubber stopper containing a centre-well (Kimble-chase Kontes) fitted with a loosely folded filter paper moistened with 0.2 ml of 1 N NaOH, and incubated for 5 h at 37 °C. 14 CO 2 in the filter paper was trapped by addition of 200 μ l of perchloric acid to the reaction mixture followed by incubation at 55 °C for 1 h. Radioactivity in the filter paper was determined by scintillation counting. Food intake studies. At 16 weeks, mice were individually housed and given standard rodent diet and water ad libitum. Cumulative food intake was measured by weighing the mouse and food every second day for 30 consecutive days. Glucose and insulin tolerance tests. Intraperitoneal glucose tolerance test (GTT) and insulin tolerance test (ITT) in Eprs S/S , Eprs A/A , and Eprs D/D mice were determined as described 22, 39 . Briefly, GTT was done after an overnight (12 h) fast followed by peritoneal injection of glucose (2 mg g −1 body weight, Sigma). ITT was performed in 6-h fasted mice by injection of 0.75 U kg −1 body weight of insulin (Sigma). Blood glucose was determined using a commercial glucometer (Contour, Bayer). Blood and serum measurements. Serum triglycerides, free fatty acids, glucose, and insulin in 12-h fasted and in 1-h post-prandial (fed) mice were determined using commercially available kits. Serum triglycerides, free fatty acids, and glucose kits were from Wako. Insulin was determined using enzyme-linked immunoassaybased, ultra-sensitive mouse insulin kit (Crystal). Determination of serum β -hydroxybutyrate (for ketone body analysis) from 6-h fasted mice was done using colorimetric assay kit from Cayman. White blood cell counts in blood freshly collected by cardiac puncture in the presence of 10 mM EDTA were determined using Advia hematology system. Faecal lipid excretion. Lipid content in mouse faeces was determined after extraction with chloroform:methanol (2:1) 45, 46 . letter reSeArCH GAIT system activity assay by in vitro translation. GAIT system activity in insulintreated adipocytes was determined by in vitro translation of capped poly(A)tailed Luc-Cp GAIT and T7 gene 10 reporter RNAs as described 35, 47 . Gel-purified RNAs were incubated with lysates from U937 monocytes and differentiated 3T3-L1 adipocytes in the presence of rabbit reticulocyte lysate and [ 35 S]methionine. Translation of the two transcripts was determined following resolution on 10% SDS-PAGE and autoradiography. Serum cytokine determination. Cytokine levels in mouse serum (100 μ g protein) were determined using mouse cytokine antibody array C3 kit (RayBiotech). Assay of liver lipid content. Mouse liver triglyceride content was determined by measurement of glycerol following saponification in ethanolic KOH (2:1, ethanol: 30% KOH) 48 . For assessment of total neutral lipid, freshly isolated liver slices were frozen in OCT, 5-μ m sections stained with Oil Red O, and analysed by densitometry using NIH image J as described 49 . Energy metabolism by indirect calorimetry. Mouse energy metabolism was determined by indirect calorimetry using the Oxymax CLAMS system (Columbus Instruments) in the Rodent Behavioural Core of the Cleveland Clinic Lerner Research Institute. Mice were housed individually in CLAMS cages and allowed to acclimate for 48 h with unrestricted excess to food and water. Thereafter, O 2 consumption (VO 2 ), CO 2 release, RER and heat generation were recorded for 24 h spanning a single light-dark cycle. 32 P metabolic labelling. Adipocytes from 500 mg WAT from wild-type and Eprs A/A mice were labelled with 150 μ Ci of 32 P-orthophosphate (MP Biomedicals) in phosphate-free DMEM medium in absence or presence of insulin (100 nM) for 4 h. EPRS was immunoprecipitated with antibodies cross-linked to protein A-sepharose beads (Sigma) in 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Triton X-100, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease/phosphatase inhibitor cocktail. Immunoprecipitated beads were washed with 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, and 0.1% Triton X-100, and then in 50 mM Tris-HCl (pH 7.6) and 150 mM NaCl. 32 added and incubated at 37 °C with 5% CO 2 for 15 min. Labelled cells were lysed in RIPA buffer (Thermo Fisher) and analysed by Tris-glycine SDS-PAGE, fixation and autoradiography. Immunoblot analysis. Cell lysates or immunoprecipitates were denatured in Laemmli sample buffer (Bio-Rad) and resolved on Tris-glycine SDS-PAGE (10, 12, or 15% polyacrylamide) prepared using 37.5:1 acrylamide:bis-acrylamide stock solution (National Diagnostics). After transfer to polyvinyl difluoride membrane, the membranes were probed with target-specific antibody, followed by incubation with horseradish peroxidase conjugated secondary antibody and detection with Amersham ECL prime western blotting detection reagent (GE Healthcare). Immunoblots shown are typical of experiments independently done at least three times. Co-immunoprecipitation. Pre-cleared cell lysates (1 mg) were incubated with antibody cross-linked to protein A-sepharose beads in detergent-free buffer containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, and EDTA-free protease/ phosphatase inhibitor cocktail. Immunoprecipitates were analysed by Tris-glycine SDS-PAGE and immunoblotting either after washing the beads three times in the same buffer or after elution, followed by neutralization with 0.2 M glycine-HCl (pH 2.6) or 50 mM Tris-HCl (pH 8.5), respectively. Fatty acid uptake assays. Fatty acid uptake assay kit (QBT, Molecular Devices) that utilizes fluorescent bodipy-C 12 , a LCFA analogue, was used to determine fatty acid uptake 50 . Differentiated 3T3-L1 adipocytes were plated at 5 × 10 4 cells per well in a 96-well plate. Adipocytes were first incubated in serum-free Hank's balanced salt (HBS) solution for 4 h, and then with 100 nM insulin and bodipy-C 12 for an additional 4 h. After 30 min, relative fluorescence was read at 485 nm excitation and 515 nm emission wavelength in bottom-read mode (SpectraMax GeminiEM, Molecular Devices).
LCFA uptake was also determined in differentiated 3T3-L1 adipocytes as cellular accumulation of [ 14 C]oleate (Perkin-Elmer). Adipocytes (10,000 cells) were seeded in a 24-well plate in DMEM with 10% calf serum overnight. Cells were serum-deprived for 4 h, treated with 100 nM insulin for 3.5 h, and then with 50 μ M of [ 14 C]oleate in HBS containing 0.1% fatty acid-free BSA for 30 min 51, 52 . Cells were washed extensively in cold HBS with 0.1% fatty acid-free BSA to remove unincorporated [ 14 C]oleate, lysed in RIPA buffer (Thermo Fisher), and centrifuged at 2000 rpm for 5 min. Supernatant radioactivity was determined by scintillation counting and normalized to protein. LCFA uptake by mouse WAT, hepatocytes, cardiac cells, BMDM, and soleus muscle strips were measured using essentially the same method 13 . Glucose uptake assay. Adipocytes from wild-type and mutant mice were preincubated for 4 h in serum-and glucose-free DMEM and then rinsed with Krebs-Ringer buffer containing 20 mM HEPES (pH 7.4), 5 mM sodium phosphate, 1 mM MgSO 4 , 1 mM CaCl 2 , 136 mM NaCl, and 4.7 mM KCl 53, 54 . Adipocytes were incubated for 4 h in the presence of 1 μ Ci of [ 14 C]2-deoxy-d-glucose (DG; Perkin-Elmer) and 100 nM insulin in the same buffer supplemented with 100 mM unlabelled 2-DG (Sigma). Uptake was stopped using ice-cold PBS containing 50 μ M cytochalasin, followed by four washes with PBS. Lysate radioactivity was determined by scintillation counting. Separation of cytosolic and membrane fractions. Membrane fraction from differentiated 3T3-L1 adipocytes was isolated by phase partitioning using Mem-PER Eukaryotic Membrane Protein Extraction Reagent Kit (Thermo-Scientific). Isolation of plasma membranes. Plasma membrane fractions from 3T3-L1 adipocytes were prepared as described 14 . Differentiated 3T3-L1 adipocytes were washed in buffer containing 250 mM sucrose, 10 mM Tris (pH 7.4), and 0.5 mM EDTA. Lysates were prepared by homogenization in the same buffer supplemented with protease and phosphatase inhibitor cocktail, and centrifuged at 16,000g for 20 min at 4 °C. The re-suspended pellet was layered onto a solution containing 1.12 M sucrose, 10 mM Tris (pH 7.4), and 0.5 mM EDTA, and centrifuged at 150,000g for 20 min at 4 °C. The resulting pellet was suspended in RIPA buffer (Sigma) and plasma membrane was obtained by centrifugation at 74,000g for 20 min at 4 °C. Data availability. All data generated are included in the published article and in the supplementary information files. Additional statistical data sets generated are available from the corresponding author upon request.
letter reSeArCH
Extended Data Figure 1 | Identification of S6K1 as EPRS Ser999 kinase. a, Screening of AGC kinase group members for phosphorylation of EPRS Ser999 by immunocomplex kinase assay and [γ -32 P]ATP-labelling with S886A linker target in U937 cells. Kinase activity using kinase-specific substrate is shown (bottom; mean ± s.e.m., n = 3). b, Specificity of S6K1 for Ser999 phosphorylation, determined by 32 P incorporation in wildtype (WT), S999A and S886 linker. c, siRNA targeting S6K1 inhibits IFNγ -stimulated EPRS phosphorylation in U937 cells determined by 32 P-labelling (mean ± s.e.m., n = 3). d, Active recombinant kinases used for in vitro phosphorylation of linker bearing S886A (Ser999 P-acceptor) mutation shows site-specific phosphorylation by S6K1. e, Raptor not rictor is required for Ser999 phosphorylation. f, siRNA targeting the S6K1 3′ UTR inhibits S6K1 expression and phosphorylation of EPRS Ser999, but not Ser886 (mean ± s.e.m., n = 3). g, Phosphorylation of S6K1 Thr389 is required for phosphorylation of EPRS. Cells were co-transfected with siRNA targeting the 3′ -UTR to knock down endogenous S6K1, and with myc-tagged wild-type or mutant S6K1 cDNA; IFNγ -stimulated EPRS phosphorylation determined by 32 P-labelling (mean ± s.e.m., n = 3). h, Cells treated as in e but followed by reciprocal co-immunoprecipitation.

Extended Data Figure 3 | Lifespan analysis of Eprs S/S , Eprs A/A and
Eprs D/D mice monitored from weaning (>21 days). a, Youngest and oldest 10% are the mean lifespan of the shortest-and longest-living 10% mice. Numbers of days are represented to nearest full day. Median and mean ± s.e.m.; are shown. b, Cox proportional hazard (CPH) regression analyses of Eprs S/S and Eprs A/A mice shows genotype as the most significant predictor of increased longevity. Longevity relative to survival days (that is, age at death) was analysed in pooled mice by CPH regression model. The four independent variables genotype, date of birth (DOB), parental ID (PID), and gender were replaced with a set of category variables. In case of genotype and gender, category represents their presence or absence. DOB and PID data were divided into multiple categories as described in the supplementary methods. Independent variables were fitted into the CPH model individually (univariate) or simultaneously (multivariate). Shown are: β (the unstandardized regression coefficient) with standard error (s.e.), the degrees of freedom (df), and the significance for each model fit. Exp(β ) for the covariate of interest is the predicted change in hazard ratio for a unit increase in the predictor, and its 95% confidence interval (CI). c, Kaplan-Meier survival curves show no change in lifespan of male, female, or combined Eprs D/D mice. Male (MC χ 2 = 0.003, P = 0.956; GBW χ 2 = 0.001, P = 0.972), female (MC χ 2 = 0.158, P = 0. 0.691; GBW χ 2 = 0.206, P = 0.650), and gender-combined (MC χ 2 = 0.079, P = 0. 0.779; GBW χ 2 = 0.076, P = 0.783). d, e, Survival and CPH regression analyses of Eprs S/S and Eprs D/D mice as described above in a and b. Male (n = 29 per group; MC χ 2 = 4.919, P = 0.027; GBW χ 2 = 4.660, P = 0.031), female (n = 28 for S6K1 +/+ and n = 26 for S6K1 −/− ; MC χ 2 = 7.927, P = 0.005; GBW χ 2 = 7.277, P = 0.007), and gender-combined (n = 26 for S6K1 +/+ and n = 55 for S6K1 −/− ; MC χ 2 = 11.78, P = 0.0006; GBW χ 2 = 11.01, P = 0.0009). e, f, Lifespan and CPH regression analyses of S6K1 +/+ and S6K1 −/− mice as described above in Extended Data Fig. 3a 
